Skip to content
    Clinical Trials

    Accelerated Partial-Breast Versus Whole-Breast Irradiation in Low-Risk Invasive Breast Cancer

    Meduri et alJournal of clinical oncology : official journal of the American Society of Clinical Oncology

    Accelerated Partial-Breast Versus Whole-Breast Irradiation in Low-Risk Invasive Breast Cancer
    In the multicenter, randomized, phase III IRMA trial (ClinicalTrials.gov identifier: NCT01803958) conducted across 35 centers, investigators evaluated whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI) in patients with low-risk invasive breast carcinoma. The study enrolled patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 nodal status. Patients were randomly assigned 1:1 to either WBI or APBI (38.5 Gy in 10 fractions twice daily) without masking.
    Between 2007 and 2019, 3,309 patients were randomized (1,652 to APBI and 1,657 to WBI), with 84 patients excluded from the modified intention-to-treat analysis. The primary end point was ipsilateral breast tumor recurrence (IBTR), with trial design assuming a 5-year IBTR rate of 4% in the WBI arm to exclude a 2% increase in the APBI arm (90% power; noninferiority margin hazard ratio [HR], 1.5).
    Over a median follow-up of 97.5 months, the 5-year cumulative incidence of IBTR was 1.0% (95% CI, 0.6 to 1.6) in the APBI arm and 0.8% (95% CI, 0.5 to 1.4) in the WBI arm. The observed HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20). Because the upper limit of the confidence interval crossed the prespecified noninferiority margin of 1.5, formal statistical noninferiority was not demonstrated. However, given the absolute difference of <0.2% and recurrence rates of ≤1% across both arms at 5 years, the authors concluded that external-beam APBI represents a reasonable clinical alternative to WBI for low-risk patients.

    Key Takeaways

    • At 5 years, cumulative incidence of ipsilateral breast tumor recurrence was 1.0% (95% CI, 0.6 to 1.6) with APBI versus 0.8% (95% CI, 0.5 to 1.4) with WBI, representing an absolute difference of <0.2%.
    • Formal statistical noninferiority was not demonstrated as the hazard ratio for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20), with the upper confidence limit exceeding the prespecified noninferiority margin of 1.5.
    Read the original sourceJournal of clinical oncology : official journal of the American Society of Clinical Oncology